Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources

WINDTREE THERAPEUTICS INC /DE/

Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.
Decision driven by limited resources and desire to advance istaroxime into broader acute heart failure.
No safety concerns were cited as the reason for termination.
CEO Jed Latkin confirmed the termination in the 8-K filing filed August 8, 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.